NEUROCRINE BIOSCIENCES INC (NBIX) Latest Company News

Oct 16, 2026, 12:30 UTC
Neurocrine Biosciences announced new real-world data describing how classic congenital adrenal hyperplasia affects patients’ clinical and day-to-day needs across life stages.
Source:
- prnewswire.com
Oct 12, 2026, 20:01 UTC
Neurocrine Biosciences announced that it will hold a conference call and webcast on November 2, 2026, to discuss its third-quarter financial results.
Source:
- prnewswire.com
Sep 30, 2026, 12:30 UTC
Neurocrine Biosciences announced that research on Prader-Willi syndrome and real-world evidence for VYKAT XR (diazoxide choline) extended-release tablets will be presented at the Foundation for Prader-Willi Research 2026 Annual Research Symposium & Family Conference in Philadelphia on Oct. 7-10, 2026.
Source:
- prnewswire.com
Sep 28, 2026, 20:27 UTC
Neurocrine Biosciences appointed Eiry W. Roberts, M.D. as Chief Medical Officer effective September 28, 2026.
Sep 28, 2026, 20:27 UTC
Neurocrine Biosciences Chief Medical Officer Sanjay Keswani, M.D. departed by mutual agreement effective September 25, 2026.
Aug 26, 2026, 11:00 UTC
Neurocrine Biosciences' IND for NBI-1117567 Phase 2 trial in Alzheimer's cognitive impairment was accepted by the US FDA, triggering a $10 million milestone payment to Nexera Pharma.
Source:
Aug 22, 2026, 07:07 UTC
Allworth Financial LP acquired a new position in Neurocrine Biosciences, Inc., purchasing 14,853 shares valued at approximately $2.50 million, as disclosed in a recent SEC filing.
Source:
- defenseworld.net
Aug 12, 2026, 15:57 UTC
Neurocrine Biosciences Inc. stock fell almost 5% on Wednesday before recovering after physicians and experts in Prader-Willi syndrome notified clinicians of some cases of deaths and severe complications potentially associated with Vykat XR (diazoxide choline).
Source:
- benzinga.com
Aug 12, 2026, 12:30 UTC
Neurocrine Biosciences announced the publication of KINECT-PRO Phase 4 study results showing INGREZZA (valbenazine) improved quality of life and daily functioning in patients with tardive dyskinesia.
Source:
- prnewswire.com
Jul 30, 2026, 20:01 UTC
Neurocrine Biosciences reported second-quarter 2026 financial results with total revenue of $959 million, up 39% year-over-year, and raised its 2026 INGREZZA net sales guidance to $2.825-$2.875 billion.
Source:
Jul 23, 2026, 20:05 UTC
Neurocrine Biosciences announced the appointment of three Senior Vice Presidents to strengthen its leadership team.
Source:
- prnewswire.com
Jun 15, 2026, 12:30 UTC
Neurocrine Biosciences presented new two-year data for its drug CRENESSITY (crinecerfont) at the ENDO 2026 conference, showing improvements in cardiometabolic outcomes in adults with classic congenital adrenal hyperplasia.

NBIX

Neurocrine Biosciences announced new real-world data describing how classic congenital adrenal hyperplasia affects patients’ clinical and day-to-day needs across life stages.

Neurocrine Biosciences announced that it will hold a conference call and webcast on November 2, 2026, to discuss its third-quarter financial results.

Neurocrine Biosciences appointed Eiry W. Roberts, M.D. as Chief Medical Officer effective September 28, 2026.

Neurocrine Biosciences Chief Medical Officer Sanjay Keswani, M.D. departed by mutual agreement effective September 25, 2026.

Neurocrine Biosciences' IND for NBI-1117567 Phase 2 trial in Alzheimer's cognitive impairment was accepted by the US FDA, triggering a $10 million milestone payment to Nexera Pharma.

Allworth Financial LP acquired a new position in Neurocrine Biosciences, Inc., purchasing 14,853 shares valued at approximately $2.50 million, as disclosed in a recent SEC filing.

Neurocrine Biosciences Inc. stock fell almost 5% on Wednesday before recovering after physicians and experts in Prader-Willi syndrome notified clinicians of some cases of deaths and severe complications potentially associated with Vykat XR (diazoxide choline).

Neurocrine Biosciences announced the publication of KINECT-PRO Phase 4 study results showing INGREZZA (valbenazine) improved quality of life and daily functioning in patients with tardive dyskinesia.

Neurocrine Biosciences reported second-quarter 2026 financial results with total revenue of $959 million, up 39% year-over-year, and raised its 2026 INGREZZA net sales guidance to $2.825-$2.875 billion.

Neurocrine Biosciences announced the appointment of three Senior Vice Presidents to strengthen its leadership team.

Neurocrine Biosciences presented new two-year data for its drug CRENESSITY (crinecerfont) at the ENDO 2026 conference, showing improvements in cardiometabolic outcomes in adults with classic congenital adrenal hyperplasia.